



YUM AND DONE.

Parasite protection couldn't be easier.
One monthly, tasty chew controls
these key parasites:^a

- FLEAS
- TICKS
- MITES
- LUNGWORM
- ROUNDWORMS

NexGard
SPECTRA[®]

Understanding owners' and practices' needs from a parasiticide

Canine parasite protection is an important part of your practice and a vital health service to dogs, owners and the local community, so you need to choose a product which delivers:

Owner needs¹⁻⁵

- › easy-to-give convenience
- › broad-spectrum efficacy[‡]
- › demonstrated palatability

[‡]As required by individual dogs



Practice needs


- › clear parasite protocols
- › make compliance easy
- › simplified stock control

Parasite protection couldn't be easier with NexGard Spectra[®]

One monthly, tasty chew provides broad-spectrum parasite cover against these key parasites:^b

Afoxolaner

Milbemycin oxime



^b NexGard Spectra[®] is indicated for the treatment of flea and tick infestations in dogs when the concurrent prevention of heartworm disease, angiostrongylosis and/or treatment of gastrointestinal nematode infestations is indicated. NexGard Spectra[®]'s mite indication is for treatment of sarcoptic mange, ear mites due to *Otodectes cynotis* and demodicosis. NexGard Spectra[®] also covers heartworm, hookworms, whipworm and eyeworm.

NexGard Spectra® eliminates fleas



The afoxolaner effect:^c



- › Fleas start dying after just **2 hours**⁶
- › All fleas are dead within **6 hours**⁶
- › Kills fleas before they can lay **eggs**⁷


^cData from NexGard® studies.⁶

NexGard Spectra® terminates ticks – in time

TICKS are a serious threat and must be killed before they can transmit disease⁸



They can also be very hard to spot:



The afoxolaner effect:^d



- › Ticks killed within **24 hours**¹³
- › Kills ticks before the transmission window for **Lyme disease and babesiosis**^{8,14}

NexGard Spectra® is effective against several different tick species, including *Ixodes ricinus*, *Ixodes hexagonus*, *Rhipicephalus sanguineus*, *Hyalomma marginatum* and *Dermacentor reticulatus*, which account for over 99% of ticks found on dogs in the UK.⁹

^dData from NexGard® studies.¹³

NexGard Spectra® prevents lungworm disease



Lungworm (*Angiostrongylus vasorum*) is endemic, found throughout the UK and Ireland¹⁵⁻¹⁷

Lungworm disease is a serious disease and can be fatal – prevention is better than cure

“You don’t want to wait until you see sick dogs”

Dr Eric Morgan, Professor of Veterinary Parasitology, Queen’s University, Belfast.

Monthly administration of NexGard Spectra® prevents angiostrongylosis in dogs and also controls environmental contamination^{7,18}

› **99.9%** reduction of larval shedding¹⁸

› **94.9%** reduction of lungworm burden¹⁸



Lifelong monthly dosing prevents lungworm disease



*If angiostrongylosis is suspected despite receiving monthly NexGard Spectra® in accordance with the SPC, Boehringer Ingelheim Animal Health will provide financial assistance for further investigation and treatment up to a maximum of £5,000 per case. Terms and conditions apply, available by contacting Boehringer Ingelheim Animal Health UK Ltd. If an attending vet suspects they have an eligible case, please contact the Technical Services Team by phone on 01344746957 or email on vetenquiries@boehringer-ingelheim.com.

NexGard Spectra® controls roundworms


Monthly worming is the most effective way to eliminate eggs shedding in the environment



WormWatch®, a recent study supported by Boehringer Ingelheim alongside leading parasitologists*, revealed...

- › 86.6% of parks in UK & Ireland positive for *Toxocara spp*¹⁹
- › 2.1 *Toxocara*-type eggs per 50g soil¹⁹
- › Roundworm eggs can live in the environment for years and therefore pose a zoonotic risk²⁹
- › 1 in 5 dogs have eggs on their paws and coats²⁰

Efficacy of NexGard Spectra® in dogs naturally infested with *T. canis*²⁵



*Study conducted by Paul M. Airs, Claire Brown, Erica Gardiner, Liz Maciag, Jamie P. Adams, Eric R. Morgan and funding by Boehringer Ingelheim UK.

NexGard Spectra[®] also manages mites^f

NexGard Spectra[®] treats skin infestations caused by three different types of mite:

Sarcoptic mange

100% efficacy

after 2 monthly treatments^{f,26}

Demodicosis

98-100% efficacy

after 3 monthly treatments^{f,27,28}

Ear mite infestations

98.5 -100% efficacy

after 1 month^{30,31}

Sarcoptic mange



Before

After

Demodicosis



Before

After

With NexGard Spectra[®] you don't have to worry about mange

^fNexGard Spectra[®]'s mite indication is for treatment of sarcoptic mange, demodicosis and *otodectes cynotis*. Refer to SPC for specific treatment regimes.

NexGard Spectra[®] is ideal for puppies

- › Can be started from just 8 weeks of age, and from 2 kg
- › Five weight ranges enable appropriate monthly dosing as puppies grow
- › Monthly dosing follows ESCCAP puppy roundworming guidelines²⁹
- › Suitable for breeding, pregnant and lactating bitches*

NexGard Spectra[®] offers all dogs and owners:

- › Easy-to-give, tasty chew
- › Immediate handling
- › Simple monthly intervals**
- › Confidence the entire dose has been received



* The safety of the veterinary medicinal product has not been established in breeding males. In breeding males, use only according to the benefit-risk assessment by the responsible veterinarian.
**Depending on the dog's risk.

See how NexGard Spectra® stands up against these key parasite threats⁹


	NexGard Spectra®	Advocate®	Bravecto®	Simparica Trio®	Credelio Plus®
Fleas	✓	✓	✓	✓	✓
Ticks	✓		✓	✓	✓
Mites	✓	✓	✓	✓	✓*
Roundworms	✓	✓		✓	✓
Lungworm	✓	✓		✓	✓
Ear Mites	✓	✓			

*Not indicated against sarcoptes mites.

⁹ The table shows activity against fleas, ticks, roundworms, lungworm and mites (sarcoptic and demodectic mange only). Some of the products listed have claims against other parasites. Refer to the Summary of Product Characteristics for each product for full details of the licensed indications.

When given the choice of both, 9/10 dogs preferred NexGard Spectra®^{4,5}

9 OUT OF 10
DOGS PREFER
NexGard SPECTRA®



NexGard Spectra® is an easy-to-give, monthly, tasty chew

^{4,5} **9 out of 10 dogs that demonstrated a preference in the studies preferred NexGard Spectra®.

^h For dogs over 60 kg, use appropriate combinations of chews.



Scan the QR code
to learn more about
NexGard Spectra®

References: 1. Ipsos. Usage & Attitudes Report for Merial Europe. 2015. 2. Ipsos. Parasite Party Pet Owner Survey: Potential Usage of Treatment. Report for Merial Europe. Report for Merial Europe 2016. 3. CMResearch. Dog owners preference study. 2014. 4. Perier N, Carithers DS, Everett WR, et al. Preference of Dogs between Two Oral Formulations of Endectoparasiticides: Nexgard Spectra® (Afoxolaner and Milbemycin Oxime) and Simparica Trio™ (Sarolaner, Moxidectin and Pyrantel). *Open Journal of Veterinary Medicine* 2020;10:155-16. 5. Perier N, Carithers DS, Everett WR, et al. Preference in Dogs of Two Oral Endectoparasiticide Formulations: NexGard Spectra® (Afoxolaner and Milbemycin Oxime) and Credelio® Plus (Lotilaner and Milbemycin Oxime). *Open Journal of Veterinary Medicine* 2021; 11, 289-298. 6. Beugnet F, deVos C, Liebenberg J, et al. Afoxolaner against fleas: immediate efficacy and resultant mortality after short exposure on dogs. *Parasite* 2014;21:42. 7. EMA. European Public Assessment Report (EPAR): NexGard Spectra chewable tablets for dogs (afoxolaner and milbemycin oxime). European Medicines Agency, London. 8. Wright I. What do dog owners need from tick protection? *Vet Times* 2018;48:10-11. 9. Abdullah S, Helps C, Tasker S, et al. Ticks infesting domestic dogs in the UK: a large-scale surveillance programme. *Parasit Vectors* 2016;9:391. 10. Abdullah S, Helps C, Tasker S, et al. Prevalence and distribution of *Borrelia* and *Babesia* species in ticks feeding on dogs in the U.K. *Med Vet Entomol* 2018;32:14-22. 11. Phipps LP, Del Mar Fernandez De Marco M, Hernandez-Triana LM, et al. *Babesia canis* detected in dogs and associated ticks from Essex. *Vet Rec* 2016;178:243-244. 12. Swainsbury C, Bengtson G, Hill P. Babesiosis in dogs. *Vet Rec* 2016;178:172. 13. Halos L, Lebon W, Chalvet-Monfray K, et al. Immediate efficacy and persistent speed of kill of a novel oral formulation of afoxolaner (NexGard™) against induced infestations with *Ixodes ricinus* ticks. *Parasit Vectors* 2014;7:452. 14. Beugnet F, Halos L, Guillot J. Textbook of Clinical Parasitology in dogs and cats Servet editorial – Grupo Asis Biomedica, S.L.; 2018. 15. Morgan ER, Tomlinson A, Hunter S, et al. *Angiostrongylus vasorum* and *Eucoleus aerophilus* in foxes (Vulpes vulpes) in Great Britain. *Vet Parasitol* 2008;154:48-57. 16. Taylor CS, Garcia Gato R, Learmount J, et al. Increased prevalence and geographic spread of the cardiopulmonary nematode *Angiostrongylus vasorum* in fox populations in Great Britain. *Parasitology* 2015;142:1190-1195. 17. McCarthy G, Ferrand M, De Waal T, et al. Geographical distribution of *Angiostrongylus vasorum* in foxes (Vulpes vulpes) in the Republic of Ireland. *Parasitology* 2016;143:588-593. 18. Lebon

W, Tielemans E, Rehbein S, et al. Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent *Angiostrongylus vasorum* infection in dogs. *Parasit Vectors* 2016;9:485. 19. Airs PM, Brown C, Gardiner E, Maciag L, Adams JP, Morgan ER. WormWatch: Park soil surveillance reveals extensive *Toxocara* contamination across the UK and Ireland. *Vet Rec* 2023 Jan;192(1). 20. Panova OA, Khrustalev AV. Dog walking brings *Toxocara* eggs to people's homes. *Veterinary Parasitology* 2018;262:16-19. 21. Ree GH, Voller A, Rowland HA. Toxocariasis in the British Isles 1982-3. *Br Med J (Clin Res Ed)* 1984;288:628-629. 22. Walsh MG, Haseeb MA. Reduced cognitive function in children with toxocariasis in a nationally representative sample of the United States. *Int J Parasitol* 2012;42:1159-1163. 23. Quattrocchi G, Nicoletti A, Marin B, et al. Toxocariasis and epilepsy: systematic review and meta-analysis. *PLoS Negl Trop Dis* 2012;6:e1775. 24. Li L, Gao W, Yang X, et al. Asthma and toxocariasis. *Ann Allergy Asthma Immunol* 2014;113:187-192. 25. Rehbein S, Knaus M, Mallouk Y, et al. Efficacy against nematode infections and safety of afoxolaner plus milbemycin oxime chewable tablets in domestic dogs under field conditions in Europe. *Parasitol Res* 2017;116:259-269. 26. Hampel V, Knaus M, Schafer J, et al. Treatment of canine sarcoptic mange with afoxolaner (NexGard Spectra®) and afoxolaner plus milbemycin oxime (NexGard®) chewable tablets: efficacy under field conditions in Portugal and Germany. *Parasite* 2018;25:63. 27. Rehbein S, de Vos C, Beugnet FC, et al. Efficacy of Once-Monthly Doses of Oral Afoxolaner and Afoxolaner/Milbemycin Oxime in a Well-Controlled Study for the Treatment of Canine Generalized Demodicosis. *Open Journal of Veterinary Medicine* 2018;08:250-265. 28. Lebon W, Beccati M, Bourdeau P, et al. Efficacy of two formulations of afoxolaner (NexGard®) and (NexGard Spectra®) for the treatment of generalised demodicosis in dogs, in veterinary dermatology referral centers in Europe. *Parasit Vectors* 2018;11:506. 29. ESCCAP. Worm Control in Dogs and Cats (2017). In: ESCCAP Guideline 01 Third Edition 2017:1-39. 30. Carithers et al. Assessment of afoxolaner efficacy against *Otodectes cynotis* infestations of dogs. 2016 *Parasite Vectors* 9, 635. (Open Access). 31. Panarese et al. Efficacy of afoxolaner for the treatment of ear mite infestation under field conditions. 2021 *Veterinary Parasitology* 300.